Pingjin Zou

Pingjin Zou

Auto-generated profile, based on publicly available information

Pingjin Zou

Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Advanced Science
Verified
Journal Article
Open access
PZPingjin Zou
Pingjin Zou
RLRui Lin
Rui Lin
ZFZengyi Fang
Zengyi Fang
JCJunyang Chen
Junyang Chen
HGHongye Guan
Hongye Guan
MCMeihua Chen
Meihua Chen
The effective and targeted treatment of resistant cancer cells presents a significant challenge. Targeting cell ferroptosis has shown remarkable efficacy against apoptosis‐resistant tumors due to their elevated iron metabolism and oxidative stress levels. However, various obstacles have limited its effectiveness. To overcome these challenges and enhance ferroptosis in cancer cells, we have developed a self‐powered photodynamic therapeutic tablet that integrates a ferroptosis inducer (FIN), imidazole ketone erastin (IKE). FINs augment the sensitivity of photodynamic therapy (PDT) by increasing oxidative stress and lipid peroxidation. Furthermore, they utilize the Fenton reaction to supplement oxygen, generating a greater amount of reactive oxygen species (ROS) during PDT. Additionally, PDT facilitates the release of iron ions from the labile iron pool (LIP), accelerating lipid peroxidation and inducing ferroptosis. In vitro and in vivo experiments have demonstrated a more than 85% tumor inhibition rate. This synergistic treatment approach not only addresses the limitations of inadequate penetration and tumor hypoxia associated with PDT but also reduces the required medication dosage. Its high efficiency and specificity towards targeted cells minimize adverse effects, presenting a novel approach to combat clinical resistance in cancer treatment.

24 August 2023 in Nano Energy
Verified
Journal Article
Closed access
TLTao Lin
Tao Lin
PZPingjin Zou
Pingjin Zou
RLRui Lin
Rui Lin
HGHongye Guan
Hongye Guan
ZFZengyi Fang
Zengyi Fang
MCMeihua Chen
Meihua Chen

2 October 2026 in Science Advances
Verified
Journal Article
Open access
RLRui Lin
Rui Lin
PZPingjin Zou
Pingjin Zou
JCJunyang Chen
Junyang Chen
ZJZhixian Jiang
Zhixian Jiang
KCKui Chen
Kui Chen
XXXinyu Xue
Xinyu Xue
Implantable wireless ultrasound microdevices for intratumoral therapy are hindered by inadequate miniaturization for deep-seated sites and toxic lead-based piezoelectrics. Here, we report an injectable, lead-free, submillimeter therapeutic dust (TheraDust; 1.0 millimeters by 1.0 millimeters by 0.9 millimeters) for ultrasound-driven wireless chemo-photodynamic combined therapy. The core of the device is a lead-free tin-doped barium titanate piezoelectric ceramic that features a multiphase coexistence at physiological temperature and exhibits a high piezoelectric coefficient ( d 33 = 460 picocoulombs per newton). The TheraDust integrates with an ultrasound-responsive drug-loaded hydrogel for precise intratumoral injection. Under programmable ultrasound, it generates light for photodynamic therapy and triggers on-demand chemotherapeutic release for enhanced treatment. In animal models of breast cancer, the device achieved potent tumor suppression, reducing the final tumor volume to less than 3% after five treatment sessions (5 minutes each) and could be retrieved minimally invasively posttreatment. This platform can be adapted to deliver a range of therapeutic stimuli wirelessly, offering a versatile strategy for treating deep-seated pathologies.